RxDoctor Payments Data

Sven Ender, MD

Clinical Cardiac Electrophysiology · Annapolis, MDNPI 1194899021

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,540 of the $4,572 with a category attached, or 77.4%. 11 manufacturers reported payments, led by Medtronic at 55.0% of the total. That places this record below the midpoint for clinical cardiac electrophysiology clinicians in MD, where the typical reported total is $15,262.

$4,572in general payments, 2019–2025

Across 100 payments — averaging $45.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • Abbott$2K
  • Merck$92
  • Amgen$52
  • Biotronik Inc.$49
  • Johnson & Johnson$39
  • plus $91 from 5 others

What the payments were for

  • Travel & lodging$1,03223%
  • Food & beverage$3,54077%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,572 in reported general payments places this provider in the 25th percentile of 63 clinical cardiac electrophysiology providers in Maryland.

See all clinical cardiac electrophysiology providers in Maryland

Medicare billing

Part B allowed, 2024
$271,050
Medicare patients
1,512
Services billed
4,008

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban248$243,190
XareltoRivaroxaban56$75,266
EntrestoSacubitril/Valsartan23$33,713
FarxigaDapagliflozin Propanediol38$24,058
Metoprolol Succinate166$3,383
Amiodarone Hcl68$3,231
Flecainide Acetate60$2,776
SotalolSotalol Hcl121$2,595
Atorvastatin Calcium141$2,357
Digoxin44$1,711
Ranolazine ErRanolazine15$1,482
Valsartan34$1,450
Losartan Potassium107$1,283
Amlodipine Besylate119$1,025
Rosuvastatin Calcium31$861

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$39$75,26656 claims
NovartisEntresto$18$33,71323 claims
AstraZenecaFarxiga$28$24,05838 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 63 clinical cardiac electrophysiology providers in Maryland.

Other clinical cardiac electrophysiology in Annapolis

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →